Haleon plc's subsidiary, Haleon US Capital LLC, announced a tender offer to repurchase up to $1.999 billion of its 3.375% fixed-rate senior notes maturing in March 2027. This move aligns with Haleon's capital allocation strategy to proactively manage and optimize its debt portfolio. The offer will expire on August 18, 2026, with settlement expected by August 21, 2026. The repurchased notes will be cancelled, and the offer is contingent on the successful issuance of new bonds, aiming to improve the company's financial flexibility.
Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...
Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...
Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...
AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...
TOMI Environmental Solutions reported a 118% year-over-year revenue increase to $2.25 million, surpassing analyst estimates of $1.84 million. The company also beat EPS expectations with a loss of $0.05 per share, better than the anticipated loss of $...
